She has made plenty of connections in her various positions shown in her description. Google her further and you will see she is both well known and respected in the small biotech circles.
This is just her bio, in summary, and I make no opinion of whether she is a candidate for CoB or the CEO position. I do think she is easily talented enough to recognize and discuss strategy for deals and will be a key person to keep happy.
Sourced verbatim from finance DOT mydailytribune DOT calm
Dr. Tina S. Nova, Ph.D., is an Independent Director of Arena Pharmaceuticals, Inc., since September 15, 2004. Dr. Nova has served as a member of our Board of Directors since September 2004. Dr. Nova has served as Senior Vice President and General Manager of Illumina Inc.’s oncology business unit since July 2014. Dr. Nova was a co-founder of Genoptix, Inc., a medical laboratory diagnostics company, and served as its President from 2000 to April 2014. Dr. Nova also served as the Chief Executive Officer of Genoptix and as a member of its board of directors from 2000 until Novartis AG acquired Genoptix in March 2011. Dr. Nova was a co-founder of Nanogen, Inc., a provider of molecular diagnostic tests, and she served as its Chief Operating Officer and President from 1994 to 2000. Dr. Nova served as Chief Operating Officer of Selective Genetics, a biotechnology company, from 1992 to 1994, and in various director-level positions with Ligand Pharmaceuticals Incorporated, a drug discovery and development company, from 1988 to 1992, most recently as Executive Director of New Leads Discovery. Dr. Nova has also held various research and management positions with Hybritech, Inc., a former subsidiary of Eli Lilly & Company, a pharmaceutical company. Within the past five years, Dr. Nova also served as a member of the board of directors of Adamis Pharmaceuticals Corporation, a biopharmaceutical company, NanoString Technologies, Inc., a provider of life science tools, and Cypress Biosciences, Inc., a pharmaceutical company. Dr. Nova was the Chair of the board of directors of BIOCOM, a life science association representing more than 650 member companies in Southern California, from March 2001 to March 2002. Dr. Nova holds a B.S. in Biological Sciences from the University of California, Irvine and a Ph.D. in Biochemistry from the University of California, Riverside.
SK was a gift and I agree, he had nothing to do with that or there has been no mention he was involved with it (Ildong was the shaker and mover there).
Craig's ability was being a better speaker. Remember also, he sold shares in the 8s and everyone gave him grief. He's been the one sitting pretty on that sale of course. At the time, his name was really out in front for the company, and rightly so, as there was so much expectations for Belviq in Europe. We all know how that turned out. He backed-up for months and we are still clueless of where they are going with EU, imho.
I'm not saying he should be CEO. Not at all., I just thought he has been on a frustrated cruise control in comparison to his eager sound 2-3 years ago. That's all.
I thought Audet has been acting wimpy the past several CCs he has participated in, and commented on it several times months ago. He quickly says his piece, adds nothing more, and sits down hoping no questions. That was not like him two years ago. He was active, energetic, and engaged to answer questions. I still think he is leaving or he was part of the group that saw that Jack needed to step down for the company to do something different and have better branding and marketing with WS.
Heather - you have a keen sense of what is happening. Your gut was right on this. Legal "quiet period" or not (which it was not), there was something and is something strange going on and it is not done.
Take this for what it is worth (zero). I believe we're going to hear both controlled and leaked tid-bits more in the next month and that there was a reason for the CFO to stick around through November 2015 (necessary due diligence prep work for response to the detailed dd statement of facts, covenants, warranties and representation questions from a possible partner/buyer). The clinical development director, who knows. He may have left out of protest unless they got JL out of there. He could not wait and got out of there frustrated and with an acceptable offer elsewhere.
But the type of vague, meaningless conference calls (more than the usual) and silence this company has had the past few months, Eisai more or less hands-off, ads not running, sales reps not calling on docs like they used to, allowing the share price to plummet without real comment, all leads me to believe this plan to have Jack leave at more or less the end of the 3Q, when the share price has been hammered to allow tunes in and scare the ba-jeezus out of retail, has been in the works for a long, long time (months and months). I suspect we'll hear a buy-in or buy-out deal prior to year's end. I'm also speculating that the interim CEO and search team will NOT rush out and replace the CEO position anytime soon for strategic flexibility to get serious about sitting down with a BP whether as a partner or for the whole.
The problem might be perceptions that would get out of control - good (over zealous thought of what could be had for the whole or parts) or bad (a measure of desperation), and who will lead those discussions and review them from a leverage of assets and potential perspective (Tina?).
For a person of your stature that posted earlier in the day not to make assumptions, you ought to have a conference with yourself in the mirror.
Yes, isn't that a nice world they live in - their game is to bet on and seek the failure of others. Who ever (whatever group of minds) initiated and invented the concept and those that approved it for liquidity purposes for the markets . . . brilliantly evil
Just two years ago they were having him out front a lot more and speaking up answering questions and he seemed, in my opinion, more into it. I cannot recall but I think it was last Spring 2015 at one of the conference calls when I noticed (I was listening) the guy seemed like he was more distant and tuned out from the whole thing. Almost sounded burned out or frustrated. He basically rushed through his presentation, took very few questions and sat the heck down.
I thought they were still enrolling at the several sites they have set up. Do they enroll fully first or do they start the trials through the process as they enroll?
Pa Ingalls to the rescue once again today . . . thanks for your wisdom. One time in your life you were wrong, but you found out later you were mistaken, right?
No pre-market trading shown as of 9:21 a.m. - all of this is weird. May be nothing but it is different given the fact it is well below $2.00 now. I would have thought there would have been at least 5 -10 thousand shares by 9:21 a.m. placed. Oh well. More of the same - flying a space ship blind at 5000 miles an hour with no instructions.
I hope you are right Heather! Hope is a bad investment technique. There are a lot of really sloppy coincidences. I just hope you are right and there is an explanation for obvious bad management communication. Worst I have experienced perhaps.